Currently out of the existing stock ratings of Dewey Steadman, 48 are a BUY (80%), 12 are a HOLD (20%).
Analyst Dewey Steadman, has had 52.12% of price targets met with an average potential upside of 24.89%, reached in 256 days on average. Previously, Dewey Steadman worked at CANACCORD, BAIRD.
Dewey Steadman has documented 117 price targets and ratings displayed on 13 stocks. The coverage was on Healthcare, Industrials sectors.
Most recent stock forecast was given on SVRA, Savara at 13-Jun-2019.
Analyst best performing recommendations are on INSM (INSMED).
The best stock recommendation documented was for PCRX (PACIRA PHARMACEUTICALS) on 2/15/2018. The price target of $32 was fulfilled within 1 day with a profit of $4.1 (11.36%), with a performance score of 113.57.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 19-Dec-2019
$15.25
$13
4 years 2 months 21 days ago
(29-Aug-2022)
2/7 (28.57%)
$0.18 (1.19%)
109
Buy Since 07-May-2020
$15.25
$29
4 years 2 months 26 days ago
(24-Aug-2022)
1/2 (50%)
$0.07 (0.46%)
47
Buy Since 16-Feb-2018
$20
4 years 2 months 26 days ago
(24-Aug-2022)
0/6 (0%)
$14.21 (245.42%)
Buy Since 19-Nov-2013
$15.25
$27
4 years 2 months 27 days ago
(23-Aug-2022)
10/14 (71.43%)
$0.09 (0.59%)
161
Buy Since 22-Oct-2019
$15.25
$30
4 years 2 months 27 days ago
(23-Aug-2022)
1/3 (33.33%)
$0.09 (0.59%)
48